Friday, June 3, 2022 Daily Archives

Sustaining Project Management Business Continuity and Partnerships Throughout COVID-19

The Avid project management office employed unique technology and communication techniques to maintain business continuity and material supply to our partners and the patients they serve throughout each COVID surges. The presentation will take a deep dive into the challenges and solutions encountered for each functional area in the biologics development and production process during the early COVID pandemic and later surges. Ultimately, discussing the lessons learned to maintain both internal and partner engagement during challenging times. Fill out the…

Virtual Demonstration of the BioSMB Multi-Column Chromatography Platform

In this virtual demonstration, our intensified processing solutions expert provides a virtual demonstration of the BioSMB multi-column chromatography platform — a fully scalable single-use solution that reduces resin usage and enables manufacturers to explore continuous processing. The demo starts with an overview of the BioSMB PD system for small-scale manufacturing and then continues with the BioSMB Process systems for clinical and commercial manufacturing. Key learning objectives: Learn how the BioSMB system offers a 3-5 fold increase in productivity, yielding up…

GreenLight for mRNA as Samsung Biologics makes first batch

Samsung Biologics has produced the first batch of drug substance for GreenLight Biosciences from its newly built mRNA facility in Korea. In June 2021, Korean contract development and manufacturing organization (CDMO) Samsung Biologics announced its intentions to enter the messenger RNA (mRNA) space through the building of a vaccine drug substance production facility at its biomanufacturing campus in Songdo, Incheon. Five months later, and the firm won a contract to make Boston-based biotech firm GreenLight’s messenger RNA COVID-19 vaccine candidate…

AbbVie betting on bispecifics but holding back on CAR-T for now

First-generation CAR-Ts are “fantastic” says AbbVie, but administrative difficulties mean bispecific antibodies are more likely to provide earlier lines of treatment in conditions like blood cancers. This week, an Evaluate Pharma report touted AbbVie to become the biggest pharma company by sales in 2028, pulling in a predicted $65.7 billion, despite the expected drop in sales of its blockbuster Humira (adalimumab). But one modality that is unlikely to play significantly in the firm’s topline is chimeric antigen receptor (CAR) T-cell…